homepage-top-section

The investigational human monoclonal antibody, OMS906 targets mannan-binding lectin-associated serine protease-3 (MASP-3), the main activator of the alternative pathway of the complement system. MASP-3 converts pro-complement factor D

This licence enables the least developed, low-income, lower middle-income as well as Sub-Saharan African countries to access the long-acting HIV prevention medicine. The deal will give the selected

Healthcare venture capital firm Lapam Capital, investment management firm Junson Capital and Dyee Capital have led the financing round. BridGene’s IMTAC platform combines ‘cutting-edge’ technologies including chemical proteomics,

PNI provides technologies, services, and solutions to develop lipid nanoparticle genomic medicines, while Replicate Bioscience designs and delivers srRNA immunotherapies. Under the terms of the deal, PNI will

Tezspire has been recommended as an add-on therapy for these patients whose condition is not sufficiently controlled with high dose inhaled corticosteroids besides another medicinal product for maintenance

The funding round was led by Enavate Sciences, a portfolio company created by Patient Square Capital. The round also saw participation of Gaingels, along with other undisclosed investors.

Under the terms of the deal, the company will be responsible for the supply of 2.5 million additional doses of liquid frozen Jynneos vaccines. The latest move follows

The drug is approved and available in the US and Europe to treat partial-onset seizures in adults. As per the terms of the agreement, SK Biopharmaceuticals has granted

New investors Sands Capital and Vivo Capital have jointly led the financing round, which has also seen participation from new investor Dreavent 6. Sofinnova Partners, New York City